EpiEP
New Haven, US · Founded 2008 · Delaware corporation · 3 known investors
EpiEP develops the EpiAccess System, a pressure-guided needle used with standard fluoroscopy to give physicians real-time confirmation of access into the pericardial cavity for epicardial heart procedures. The technology supports treatments such as ventricular tachycardia, atrial fibrillation, and left atrial appendage ligation, and serves cardiac electrophysiologists and interventional cardiologists.
Founders & leadership
EpiEP was founded in 2008 by George T. Gillies and Jonathan Sackier.
GT
George T. GilliesCo-founder
JS
Jonathan SackierCo-founder
PM
Pamela M. BunesExecutive
Board
KD
ML
Mary Lake PolanBoard director
DC
Don CrawfordBoard director
TB
Thomas BrooksBoard director
DW
Dan WagnerBoard director
RE
Russell E. TweeddaleBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$16.6M disclosed across 4 rounds · 2011–2018
▶$156.4KraisedDec 2018 · 3 investors · Other Health CareRule 506(b)
▶$156.4KraisedDec 2018 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Thomas BrooksDirector
- Dan WagnerDirector
- Don CrawfordDirector
- Mary Lake PolanDirector
- Gene SandersDirector
- Pamela M BunesExecutive Officer, Director
- Konstantine DrakonakisDirector
- Offering amount
- $372K
- Amount sold
- $156.4K
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedMay 2017 · 25 investors · Other Health CareRule 506(b)
▶$1.4MraisedMay 2017 · 25 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Konstantine DrakonakisDirector
- Don CrawfordDirector
- Mary Lake PolanDirector
- Pamela M. BunesExecutive Officer, Director
- Gene SandersDirector
- Thomas BrooksDirector
- Dan WagnerDirector
- Offering amount
- $1.5M
- Amount sold
- $1.4M
- Sales commissions
- $58.2K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- May 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.4MraisedSep 2016 · 55 investors · Other Health CareRule 506(b)
▶$13.4MraisedSep 2016 · 55 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Don CrawfordDirector
- Konstantine DrakonakisDirector
- Thomas BrooksDirector
- Mary Lake PolanDirector
- Dan WagnerDirector
- Pamela M BunesExecutive Officer, Director
- Offering amount
- $17.8M
- Amount sold
- $13.4M
- Sales commissions
- $439.4K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- May 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedJan 2012 · 9 investors · Other Health CareRule 506(b)
▶$1.6MraisedJan 2012 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- George T. GilliesDirector
- Pamela M. BunesExecutive Officer, Director
- Jonathan SackierDirector
- Russell E. TweeddaleDirector
- Offering amount
- $2.3M
- Amount sold
- $1.6M
- Proceeds to insiders
- $240K
- First sale
- Dec 2011
- Incorporated
- Corporation, Delaware, 2008
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Startup Health9 shared keywordsStartUp Health operates a private global membership community for health innovators — including founders, healthcare executives, investors, and clinicians — offering a member network app, live AMAs and fireside chats, in-person event access, and a content library. It focuses on connecting and supporting people working on digital health and healthcare innovation.
Eyecool Eyecool Stealth Mode8 shared keywordsCHV is a venture capital firm that invests in medical technology companies developing therapeutic devices, diagnostic tools, and digital health solutions to improve patient outcomes.
Neuron236 shared keywordsNeuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease. It aims to match patient subsets defined by genetic drivers with targeted therapies for conditions such as Parkinson's and Alzheimer's.
Veradigm6 shared keywordsVeradigm provides solutions for healthcare stakeholders including payers, providers, and life science companies, leveraging its provider network to deliver data insights and research acceleration capabilities. The company operates within the healthcare ecosystem to improve patient access and enable clinical research.
Companies competing with EpiEP for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does EpiEP do?
- EpiEP develops the EpiAccess System, a pressure-guided needle used with standard fluoroscopy to give physicians real-time confirmation of access into the pericardial cavity for epicardial heart procedures. The technology supports treatments such as ventricular tachycardia, atrial fibrillation, and left atrial appendage ligation, and serves cardiac electrophysiologists and interventional cardiologists.
- Who founded EpiEP?
- EpiEP was founded by George T. Gillies, Jonathan Sackier in 2008.
- Who are EpiEP's investors?
- EpiEP's investors include LaunchCapital, Connecticut Innovations, Portfolia.
- How much funding has EpiEP raised?
- EpiEP has disclosed $16.6M raised across 4 rounds.
- Where is EpiEP headquartered?
- EpiEP is headquartered in New Haven, US.